Metoprolol
- PMID: 30422518
- Bookshelf ID: NBK532923
Metoprolol
Excerpt
Metoprolol, a widely employed β-adrenergic antagonist, is pivotal in cardiovascular pharmacology. Metoprolol is indicated primarily for conditions such as hypertension, angina pectoris, heart failure, and arrhythmias. The medication exerts its therapeutic effect by selectively inhibiting β-1 adrenergic receptors, resulting in diminished cardiac contractility, heart rate, and blood pressure. While generally well-tolerated, metoprolol may elicit adverse effects, including bradycardia, hypotension, and bronchospasm, necessitating vigilant patient monitoring. Contraindications encompass conditions such as severe bradycardia, heart block, and decompensated heart failure, warranting cautious use of alternative therapies. An adept understanding of metoprolol's multifaceted clinical profile empowers healthcare professionals to navigate treatment decisions judiciously, promoting favorable patient outcomes in cardiovascular management.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Papadopoulos DP, Papademetriou V. Metoprolol succinate combination in the treatment of hypertension. Angiology. 2009 Oct-Nov;60(5):608-13. - PubMed
-
- Olsson G. Thromboatherosclerotic complications in hypertensives: results of the Stockholm Metoprolol (secondary prevention) Trial. Am Heart J. 1988 Jul;116(1 Pt 2):334-8. - PubMed
-
- Vedin A. Ten years of clinical experience with metoprolol. J Cardiovasc Pharmacol. 1987;10 Suppl 2:S80-5. - PubMed
-
- Prakash A, Markham A. Metoprolol: a review of its use in chronic heart failure. Drugs. 2000 Sep;60(3):647-78. - PubMed
-
- Hjalmarson A, Herlitz J, Holmberg S, Rydén L, Swedberg K, Vedin A, Waagstein F, Waldenström A, Waldenström J, Wedel H, Wilhelmsen L, Wilhelmsson C. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983 Jun;67(6 Pt 2):I26-32. - PubMed
Publication types
LinkOut - more resources
Full Text Sources